NEWS RELEASE

NIPPON SHINYAKU CO., LTD.

February 27, 2024

VILTEPSO® (viltolarsen) injection:
Phase II trial (Galactic53 trial) Data Scheduled for Presentation
at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Kyoto, Japan, February 27, 2024 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced that it will present a poster presentation on the results of the Phase II trial (Galactic53 trial) of VILTEPSO® (viltolarsen), for the treatment of Duchenne muscular dystrophy (DMD), at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference being held in Florida from March 3-6 (U.S. time).

In the Galactic53 trial, VILTEPSO® was administered once weekly for 48 weeks to ambulatory and non-ambulatory DMD patients aged 8 years and older who are amenable to exon 53 skipping therapy.

The title of the poster is "Pulmonary and motor function in ambulatory and non-ambulatory participants with Duchenne muscular dystrophy treated with viltolarsen." In this presentation, data on the safety and efficacy (respiratory function and motor function) will be reported.

To participate in the Conference, you will need to register (charged) on the website https://www.mdaconference.org/.

About VILTEPSO®

VILTEPSO® is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VILTEPSO® received marketing authorization under the conditional early approval system in Japan in March 2020 and became commercially available in Japan in May of the same year. In the United States, it received accelerated approval from the US Food and Drug Administration (FDA) in August 2020 and has been marketed through NS Pharma, Inc.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit https://www.nspharma.com. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact
Corporate Communications Dept., Nippon Shinyaku Co., Ltd.
FAX: +81-75-321-9128